Ariad Pharmaceuticals, Inc.

Ariad Gene Therapeutics, Inc.

Victor M Rivera

William C Shakespeare

James Edward Rothman

Timothy P Clackson

Sen Zhang

The invention features a method for treating patients who have an ALK-driven cancer, which is, or has become, refractory to one or more of crizotinib, CH5424802 and ASP3026, or which bears an ALK mutation identified herein, by administering a compound of formula (I) to the patient. The invention also features methods, kits, and compositions for characterizing ALK-driven cancers to determine whether they express an ALK mutant.

Methods for inhibiting cell proliferation in ALK-driven cancers

Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells expressing such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.

Growing community of inventors

Arlington, MA, United States of America

Victor M Rivera